High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression-Reference-Cited by-同舟云学术

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

Published:2016-08 Issue: Volume:98 Page:59-61
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ou Sai-Hong Ignatius,Agarwal Nikita,Ali Siraj M.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci. Transl. Med.,2011

2. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin. Cancer Res.,2013

3. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Jänne;N. Engl. J. Med.,2015

4. Development and validation of a linical cancer genomic profiling test based on massively parallel DNA sequencing;Frampton;Nat. Biotechnol.,2013

5. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov.,2014

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer;Signal Transduction and Targeted Therapy;2024-03-09

2. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer;Cancer Research Communications;2024-02-08

3. Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors;European Journal of Medicinal Chemistry;2023-12

4. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches;Cancers;2023-09-14

5. The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells;Experimental Cell Research;2023-09